Loading...
XSHE
300122
Market cap4.86bUSD
Oct 09, Last price  
13.70CNY
1D
0.81%
1Q
12.57%
Jan 2017
-16.82%
IPO
-25.38%
Name

Chongqing Zhifei Biological Products Co Ltd

Chart & performance

D1W1MN
XSHE:300122 chart
P/E
—
P/S
3.66
EPS
—
Div yield, %
5.89%
Shrs. gr., 5y
8.39%
Rev. gr., 5y
-10.02%
Revenues
8.96b
-65.64%
492,428,885590,335,676604,047,459737,313,591628,740,039760,326,497780,177,947800,937,516712,738,058445,947,1511,342,568,6325,228,307,72710,587,318,31115,190,366,23030,652,415,90638,264,011,33152,917,767,02826,069,711,3618,958,435,384
Net income
-14.72b
L
152,009,074190,051,259231,589,722256,788,078196,383,625215,045,381130,347,847148,003,993197,401,92732,520,316432,275,4061,451,366,5312,366,438,7383,301,326,83110,208,548,4577,538,999,7018,069,868,2062,018,478,516-14,723,152,849
CFO
5.17b
111,659,461141,584,417210,612,67454,190,253221,247,243112,891,820221,576,180161,388,660223,448,28389,954,889203,609,676585,590,1951,366,993,8303,496,688,9408,507,591,8171,989,033,1058,996,369,98105,167,319,683
Dividend
Dec 25, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chongqing Zhifei Biological Products Co., Ltd. is a Chinese firm primarily engaged in the innovation, manufacturing, and commercialization of vaccines and other biological pharmaceuticals within the country. The company's establishment dates back to 2009, and its main operational base is located in Chongqing, China.

Key people

Shilong Yang
Staff Elected Director · since 2025
Independent Director · since 2021
Independent Director · since 2021
Independent Director · since 2024
IPO date
Sep 28, 2010
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
重庆市江北区金源路7号25-1至25-8
江北区, CQ 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT